Compare Mesoblast Limited (MESO) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs NRG Energy Inc — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while NRG Energy Inc trades at $133.36 (market cap $27.55B). The key difference: NRG Energy Inc is far larger — about 12.7× Mesoblast Limited's market cap, and NRG Energy Inc pays a 1.46% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | NRG | |
|---|---|---|
Market Cap | $2.17B | $27.55B |
Sector | Technology | Utilities |
52-Week High | $20.96 | $184.03 |
52-Week Low | $12.88 | $120.65 |
Enterprise Value | $2.17B | $51.38B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
NRG Energy trades at $131.02, up 1.48% with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with strong revenue growth to $30.71B but thin net margins of 0.74%. Analyst consensus remains bullish with a $196.33 price target, representing 50% upside potential from current levels. Recent news highlights expanding generation capacity and data center deals as growth catalysts.
The outlook balances strong analyst support against elevated valuation multiples and technical weakness. Key opportunities include power demand growth and strategic positioning, while risks involve margin pressure and debt levels exceeding 56% of assets. The upcoming Q2 2026 earnings report on August 4 will be critical for confirming growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
